CURRICULUM VITAE

PERSONAL INFORMATION

Name	Patricia VELLA BONANNO
Nationality	Maltese

WORK EXPERIENCE

June 2013 – to date	Advanced Pharmacist Practitioner Superintendence of Public Health, Ministry for Health, Malta
	Expert in pharmaceutical policy and regulation: advise to the SPH; Member and Secretariat to the Valletta Technical Committee, a group of ten European Member States collaborating together for increased access to medicines. Regulation, inspection, quality management and setting of standards: health care services; substances of human origin; blood, tissues and cells, organs Since March 2020: Lead of the Helpline Team within the Public Health COVID Response Team
	National Authority for public health and for regulation, licensing and monitoring of health care services, licensing and regulation of facilities operating in substances of human origin.
March 2004 – June 2013	Chief Executive Officer Medicines Authority, Malta
	The Medicines Authority is the National Competent Regulatory Authority which sets recommendations for the licensing and post-authorisation monitoring of medicinal products and for the licensing of pharmaceutical activities. Main responsibilities included scientific and regulatory evaluation and decisions, leadership and management of the agency, quality management and continuous quality improvement. Was a member of the Management Board of the European Medicines Agency (EMA), member of the Heads of Medicines Agencies Network and alternate member of the Committee for Human Medicinal Products (CHMP).
	Regulatory Authority for medicinal products and pharmaceutical activities.
June 1991 – February 2004	Pharmacist, Senior Pharmacist, Principal Pharmacist Various departments, Ministry for Health, Malta
	Setting and monitoring of national pharmaceutical policy; Secretary to the national Drugs and Therapeutics Committee and evaluation of new medicines for the public health services; clinical pharmacy services; hospital pharmacy services including reconstitution of chemotherapy; procurement of medicines and medical devices
	National pharmaceutical policy; Public health care service; pharmaceutical services
2019 – to date	Occasional lecturer Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Gozo
2017 – to date	Visiting Professor
	Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, UK
2017 – to date	Member of the Supervisory Team for a PhD Student
	School of Pharmacy and Life Science, Robert Gordon University, Aberdeen, Scotland
1995 – to date	Academic Department of Clinical Pharmacology and Therapeutics, University of Malta
	Occasional lecturer, supervisor for dissertations, examiner for Master level and PhD dissertations, sitting on the Board of Examiners. During Academic Year 2016/ 2017held a T2 appointment as a Visiting Senior Lecturer replacing a Senior Lecturer in pharmacology (pharmacokinetics) who was on sabbatical.

EDUCATION AND TRAINING (in chronological order)

2020	Certificate of Achievement Level 5 EMCS, City of Glasgow College, Ministry for Health, EU funds for Malta 2014-2020 Managing People Professionally Programme, 10 SCQF Credits at SCQF Level 8 (EQF Level 5) as part of the Provision of Non-Technical Skills Training for Healthcare Personnel Project (ESF 02.052)
2016-2019	MA in Management, Distinction Level 7 University of Malta Dissertation title: Attitudes, perceived impacts and motivational factors for European Member State collaboration for pricing and reimbursement of medicines: a review of the evidence Postgraduate Certificate in Evidence-Based Management and Effective Decision Making
2013-2014	CMI Level 5 Certificate in Management and Leadership (QCF) Level 5 Chartered Management Institute, United Kingdom - Meeting stakeholder and quality needs; conducting a management project
1998-2003	PhD Level 8 The Robert Gordon University, Aberdeen, Scotland Thesis title: 'The Managed Entry of New Drugs into a National Health Service: a case study for Malta' Area of study: Therapeutics, pharmaceutical policy, pharmaceutical public health, medicines management, medicines reimbursement within a national health service Methodology: developmental evaluation, case study, action research methodology Sources of funding: a British Chevening Scholarship awarded by the Foreign and Commonwealth Office and a Commonwealth Scholarship
1992 - 1995	MSc in Clinical Pharmacy Level 7 The Queen's University of Belfast, Belfast. N. Ireland - Study modules, examination, practice log - Dissertation: Introducing new drugs – current hospital practice
1987 - 1991	Bachelor of Pharmacy (Hons) Level 6 University of Malta, Department of Pharmacy, Msida, Malta - Pharmacy, pharmacology, therapeutics, pharmacokinetics, pharmaceutics, Medicinal chemistry and chemistry, physiology and biochemistry, mathematics and statistics - Dissertation: Breast Cancer in Malta

PERSONAL SKILLS

Mother tongue(s)	Maltese and English

Other languages	Understanding		Speaking		Writing
	Listening	Reading	Spoken interaction	Spoken production	
Italian	Independent user	Independent user	Basic user	Basic user	Independent user
French	Basic user	Basic user	Basic user	Basic user	Basic user

Communication and social skills	**Communication:** capable of building, supporting and defending a theme or an idea; leading and participation in one to one and small group meetings including management meetings, HR meetings, as an inspector of healthcare services; chairing, participation and delivery of presentations at committees and meetings; participation at fora organised by various organisations such as the European Commission, the Council, European Medicines Agency and the World Health Organisation. **Teamwork:** was chair of the management team at the Medicines Authority; was member of the Head of Medicines Agencies Network; member of inspection teams both as lead as well as an inspector. **Travel and experience abroad:** PhD conducted over a period of 5 years and involved long periods of study in Aberdeen; travelled widely for meetings to London and Brussels and to various different European countries.
Computer skills	Good command of Microsoft Office ™ tools
Organisational/ managerial skills	**Leadership and management:** held higher management positions since 1998. The post of CEO at the Medicines Authority (2004-2013) involved a top management position and included chairing of the Management Team of the Authority and responsibility for administrative, quality and financial management of the Authority. The Medicines Authority was a newly set organisation and my leadership focused on the growth of the organisation and the development of its resources to achieve the objectives and targets of the organisation. The Medicines Authority developed a strong quality management system with continuous quality improvement. Was a member of the Management Board of the European Medicines Agency (an EU Agency) for nine years. Currently a Member of the Management Board of the European Centre for Disease Prevention and Control (ECDC) in Stockholm. **HR management:** The Medicines Authority had a staff of 42 FTE; performed performance targets and monitoring, appraisals, and recruitment. **Collaboration:** I work well and collaborate with other officers, inspectors and sections within the Superintendence of Public Health and within the Department of Health; Secretariat of the Valletta Technical Committee **Personal and time management:** I maintained full time employment throughout my working life and simultaneously studied and later kept my family with two children. I have maintained academic activity in parallel.
Job-related skills	**Knowledge:** throughout my career I kept on studying and researching in synchronisation with the requirements of my job. When recently my job was changed to regulation of substances of human origin, I started formal and informal training and research in line with the new job requirements. I also proceeded with increasing my knowledge and participation in research and publication in my area of specialisation and follow-up from my PhD. **Project management:** throughout my career I was assigned a number of projects, particularly the development and implementation of a number of new services including clinical pharmacy services at St. Luke's Hospital, cytotoxic reconstitution services, the Medicines Authority and more recently inspection of services related to substances of human origin. **Quality management and continuous quality improvement:** My PhD dealt with change management particularly the changes required to support the development of the pharmaceutical sector and pharmaceutical policy following the introduction of EU legislation in line with Malta's accession into the EU. At the Medicines Authority I led the system of quality management, internal and external audit, and continuous quality improvement. As part of the inspectorate I check the implementation of quality management systems of the different services inspected and support improvement measures.
Other skills	**Research:** my main research project was my PhD, which involved action research methodology and was related to my work practice. I have special interest in collaboration and synergy between research and practice, particularly to improve policy and decision making. My specialisation is in pharmaceutical regulation and pharmaceutical policy.

ADDITIONAL INFORMATION

Current activities/positions	- Member of the Management Board of the European Centre for Disease Prevention and Control (ECDC) (2017 – ongoing) - Member of the Piperska Group – Rational prescribing (2016 – ongoing) - Member and Secretariat of the Valletta Technical Committee (2017 – ongoing)
Main previous activities/positions	- Participation at meetings of the European Commission, DG SANTE, Competent Authorities for Tissues and Cells and Competent Authorities for Blood and Blood Components (2013 – 2017) - Member of the HORIZON 2020 Advisory Group, Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing/Processing (NMBP), European Commission, DG for Research & Innovation, Directorate D – Industrial Technologies (2016 – 2017) - Member of COST Action IS1304: Expert Judgment Network: Bridging the Gap Between Scientific Uncertainty and Evidence-Based Decision Making (2014 – 2017) - Represented Malta on the States Representative Group of the Innovative Medicines Initiative (2005 to 2013). - Represented Malta at meetings of the Council and of the European Commission in the area of Pharmaceuticals, such as the Pharmaceutical and Medical Devices Working Party and the Standing Committee (2004 – 2013). - Was member of the Management Board of the European Medicines Agency, which is an institution of the EU (2004 -2013). - Was member on the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMEA) for 2 years (2004 – 2005) and was then CHMP alternate member until 2013. - Was the Maltese Representative on the Working Group on Pricing of the Pharmaceutical Forum of DG Enterprise (2005-2008). - Served as an appointed member of the Pharmacy Council (the regulatory body for the pharmacist profession in Malta) for 6 years. - From 1998 to 2003 I was Secretary to the Drug and Therapeutics Committee in Malta (the reimbursement committee of the National Health Services).
Training	- Various short courses and training sessions e.g. in management and leadership, project management, quality improvement, pharmaceutical regulation - EUSTITE 2014/2015 Training Course for Tissues and Cell Inspectors: European Union Standards and Training for Inspection of Tissue Establishments - Participated in the Course Perspectives on Regulation delivered by the Anglia Ruskin University of the UK, held between 16th February and 22nd April 2015. Topics covered included: perspectives on regulation (overview), risk and risk paradigms, controlling risk, systems and power, regulatory objectives, regulatory power and accountability, public and private interest models of regulation, law and institutions, institutions and practice. - List of Continuing Professional Development activities and Certificates below

PROFESSIONAL REGISTRATIONS AND MEMBERSHIPS

- Registered as a pharmacist with the Pharmacy Council, Malta Reg. No. 514
- Fellow of The Royal Society for Public Health (FRSPH), United Kingdom
- Associate Member of the Centre for Evidence-Based Management

PUBLICATIONS AND PRESENTATIONS (CHRONOLOGICAL ORDER)

Vella, P., 1991. *Breast cancer in Malta*. B.Pharm. (Hons) thesis. The University of Malta, Malta.

Vella, P., 1995. *Introducing new drugs – current hospital practice*. M.Sc. thesis, The Queen's University of Belfast, United Kingdom.

Vella, P., 1999. *Development of a model to support the practice for the introduction of new drugs into the NHS in Malta*. Poster. 4th Maltese Medical School Conference, Malta.

Vella, P. and Mackie, C.A., 2000. *Do consultants change their views for prescribing new drugs?* Poster. European Society of Clinical Pharmacy Conference, Basel, Switzerland.

Vella Bonanno, P. and Mackie, C.A. and Mallia, C., 2001. *Do consultants accept the development of the role of the pharmacist within the hospitals of the Government Health Services in Malta?* Poster. 2nd European Society of Clinical Pharmacy Spring Conference, Malta.

Zarb, P., Borg, M.A. and Vella Bonanno, P., 2001. *The role of a designated clinical pharmacist to promote rational antibiotic prescribing.* Poster. 2nd European Society of Clinical Pharmacy Spring Conference, Malta.

Vella Bonanno, P., Sciberras, J., Zammit, P. and Spiteri, S., 2001. *Integrating patients' views in the process for improving community dispensing practice within pharmacies of the NHS in Malta.* Poster. 2nd European Society of Clinical Pharmacy Spring Conference, Malta.

Vella Bonanno, P., Mackie, C.A. and Mallia, C., 2001. *Consultants' ranking of criteria to be considered when deciding on whether to introduce a new drug on the formulary.* Poster: 5th Congress of the European Association of Clinical Pharmacology and Therapeutics, Odense, Denmark. Abstract: *Pharmacology & Toxicology*, 89 (1), pp. 44.

Vella Bonanno, P., Mackie, C.A. and Mallia, C., 2002. *Review of the formulary management system within the NHS in Malta.* Poster. 7th European Forum on Quality Improvement in Health Care, Edinburgh, Scotland.

Vella Bonanno, P., 2002. Towards a framework for the continual improvement of healthcare. *The Chronic Ill*, 6, (Summer), pp.15 - 17. http://www.mcppnet.org/publications/ISSUE06.PDF

Vella Bonanno, P., 2003. *The managed entry of new drugs into a national health service: a case study for Malta*. PhD thesis. The Robert Gordon University, Aberdeen, United Kingdom. The British Library http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.520359

Heads of Medicines Agencies, 2007. *Availability of human medicinal products*. Report of Task Force of HMA MG. http://www.hma.eu/Availability_medicines_HMAMG_TF_Report.pdf

Vella Bonanno, P., 2008. *Availability of medicines, a case study for Malta*. Oral presentation. International Conference 'Competition and pharmaceutical policy in European law: the challenges for small European markets', University of Iceland and Ministry of Health, Iceland.

Borg, J.J., Robert, J.L., Wade, G., Aislaitner, G., Pirozynski, M., Abadie, E., Salmonson, T. and Vella Bonanno, P. 2009. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee for Medicinal Products for Human use during European Centralised Marketing Authorisation submissions for chemical entity medicinal products. *Journal Pharm Pharmaceut Sci,* 12 (2), pp. 175 - 192. https://ejournals.library.ualberta.ca/index.php/JPPS/article/view/6525/5440

Vella Bonanno, P., 2010. *The managed entry of new drugs into a national health service*. Lambert Academic Publishing, Germany. ISBN 978-3-8383-9426-8

Vella Bonanno, P., Vella, H. and Cilia, M., 2011. A strong and supportive regulatory framework for medicines. *The Economic Update*, 10, pp. 24-25.

Vella Bonanno, P. and Flores, G., 2011. Seven years of EU pharmaceutical regulation in Malta. *WHO Drug Information,* 25 (4), pp.343-353.http://www.who.int/medicines/publications/druginformation/issues/25_4.pdf

Flores, G. and Vella Bonanno, P., 2012. Enhancing the choice and use of medicines: an overview of the Medicines Authority's strategy to empower patients and consumers and support health care professionals. *Journal of the Malta College of Pharmacy Practice,* 18 (Summer), pp. 29-30. http://www.mcppnet.org/publications/ISSUE18-10.pdf

Tanti, A., Camilleri, M., Vella Bonanno, P. and Borg, J.J., 2013. Medication errors through a national pharmacovigilance database approach: A study for Malta. *The International Journal of Risk and Safety in Medicines*, 25 (1), pp. 17-27.

Mifsud, I. and Vella Bonanno, P., 2015. Medicines management in the palliative care of cancer patients. *Journal of the Malta College of Pharmacy Practice,* 21, pp. 4-12. http://www.mcppnet.org/publications/ISSUE21-2.pdf

De Bruijn, W., Ibanez, C., Frisk, P., Pedersen, H.B., Alkan, A., Vella Bonanno, P., Brkičić, L.S., Bucsics, A., Dedet, G., Eriksen, J., Fadare, J.O., Fürst, J., Gallego, G., Godói, I.P., Guerra Júnior, A.A., Gürsöz, H., Jan, S., Jones, J., Joppi, R., Kerman, S., Laius, O., Madzikwa, N., Magnússon, E., Maticic, M., Markovic-Pekovic, V., Massele, A., Ogunleye, O., O'Leary, A., Piessnegger, J., Sermet, C., Simoens, S., Tiroyakgosi, C., Truter, I., Thyberg, M., Tomekova, K., Wladysiuk, M., Vandoros, S., Vural, E.H., Zara, C., and Godman, B. 2016. Introduction and utilisation of high priced HCV medicines across Europe; Implications for the future. *Frontiers in Pharmacology*, 22 July 2016. http://journal.frontiersin.org/article/10.3389/fphar.2016.00197/full

Wild, C., Grossmann, N., Vella Bonanno, P., Bucsics, A., Furst, J., Garuoliene, K., Godman, B., Gulbinovic, J., Jones, J., Pomorski,K., Emprechtinger, R. 2016. Utilisation of the ESMO-MCBS in practice of HTA. *Annals of Oncology*. Doi.10.1093/annonc/mdw297. http://annonc.oxfordjournals.org/cgi/reprint/mdw297?ijkey=dzAgz62Of0qGmhB&keytype=ref

Ermisch, M., Bucsics, A., Vella Bonanno, P., Arickx, F., Bybau, A., Bochenek, T., Casteele, M., Diogene, E., Furst, J., Garuolien, K., van der Graaff, M., Gulbinovic, J., Haycox, A., Jones, J., Joppi, R., Laius, O., Langer, I., Martin, A.P., Markovic-Pekovic, V., McCullagh, L., Magnusson, E., Nilsen, E., Selke, G., Sermet, G., Sermet, C., Simoens, S., Sauermann, R., Schuurman, A., Ramos, R., Vlahovic-Palcevski, V., Zara, C., Godman, B. 2016. Payers' views of the changes arising through the possible adoption of Adaptive Pathways. *Frontiers in Pharmacology*. DOI: 10.3389/fphar.2016.00305. http://journal.frontiersin.org/article/10.3389/fphar.2016.00305/full Pubmed https://www.ncbi.nlm.nih.gov/<WBR>pubmed/27733828

Bochenek, T., Godman, B.B., Bucsics, A., De Weerdt, E., Furst, J., Gialite, E.,Hotvedt, T.A., Huys, I., Inotai, A., Joppi, R., Malaj, A., Margus, K., Markovic-Pekovic, V., Simoens, S., Slaby, J., Sovic Brkicic, L., Gurpinar, E.U., Vella Bonanno, P., Warminska, E.J., Pilc, A. 2016. Systemic solutions, legislative and organisational frameworks aimed to prevent or mitigate drug shortages in European Countries. Abstract PHP34, ISPOR 19th Annual European Congress Research Abstracts. *Value in Health*. 19: A 445. http://www.valueinhealthjournal.com/article/S1098-3015(16)31938-6/pdf

Vella Bonanno, P., Ermisch, M., Godman, B., Martin, A.P., Van Den Bergh, J., Bezmelnitsyna, L., Bucsics, A., Arickx, F., Bybau, A., Bochenek, T., van de Casteele, M., Diogene, E., Eriksson, I., Furst, J., Gad, M., Greiciute-Kuprijanov, I., van der Graaf, M., Gulbinovic, J., Jones, J., Joppi, R., Kalaba, M., Laius, O., Langner, I., Mardare, I., Markovic-Pekovic, V., Magnusson, E., Melien, O., Mashkov, D.O., Petrova, G.I., Selke, G., Sermet, C., Simoens, S., Schuurman, A., Ramos, R., Rodrigues, J., Zara, C., Zebedin-Brandl, E., Haycox, A. 2017. Adaptive Pathways: Possible Next Steps for Payers in Preparation for their Potential Implementation. 2017. *Frontiers in Pharmacology.* August 2017, Volume 8, Article 497. doi: 10.3389/fphar.2017.00497. http://journal.frontiersin.org/article/10.3389/fphar.2017.00497/full; https://www.ncbi.nlm.nih.gov/pubmed/28878667

Ferrario, A., Arāja, D., Bochenek, T., Čatić, T., Dankó, D., Dimitrova, M., Fürst, J., Greičiūtė-Kuprijanov, I., Hoxha. I., Jakupi, A., Laidmäe, E., Löblová, O., Mardare, I., Markovic-Pekovic, V., Meshkov, D., Novakovic, T., Petrova, G., Pomorski, M., Tomek, D., Voncina, L., Haycox, A., Kanavos, P., Vella Bonanno, P., Godman, B. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. 2017. *Pharmacoeconomics*. Dec; 35(12):1271-1285. doi: 10.1007/s40273-017-0559-4. https://www.ncbi.nlm.nih.gov/pubmed/28836222

Vella Bonanno, P. Systematic Review: a cornerstone to promote the uptake of research findings for evidence-based practice. 2017. *Journal of the Malta College of Pharmacy Practice.* 23: 35-40. http://www.mcppnet.org/publications.htm

Moorkens, E., Vulto, A.G., Huys, I., Dylst, P., Godman, B., Keuerleber, S., Claus, B., Dimitrova, M., Petrova, G., Sović-Brkičić, L., Slabý, J., Šebesta, R., Laius, O., Karr, A., Beck, M., Martikainen, J.E., Selke, G.W., Spillane, S., McCullagh, L., Trifirò, G., Vella Bonanno, P., Mack, A., Fogele, A., Viksna, A., Władysiuk, M., Mota-Filipe, H., Meshkov, D., Kalaba, M., Mencej Bedrač, S., Fürst, J., Zara, C., Skiöld, P., Magnússon, E., Simoens, S. Policies for biosimilar uptake in Europe: An overview. 2017. *PLoS One.* Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017, https://www.ncbi.nlm.nih.gov/pubmed/29284064

Bochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Bezovic, Z., Vella Bonanno, P., Bucsics, A., Davidescu, M., De Weerdt, E., Duborija-Kovacevic, N., Furst, J., Gaga, M., Gailīte, E., Gulbinovič, J., Gürpınar, EU., Hankó, B., Hargaden, V., Hotvedt, TA., Hoxha, I., Huys, I., Inotai, A., Jakupi, A., Jenzer, H., Joppi, R., Laius, O., Lenormand, M-C., Makridaki, D., Malaj, A., Margus, K., Marković-Peković, V., Miljković., N., de Miranda, JL., Primožič, S., Rajinac, D., Schwartz, DG., Šebesta, R., Simoens, S., Slaby, J., Sović-Brkičić, L., Tesar, T., Tzimis, L., Warmińska, TL., Godman, B. 2018. Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. *Frontiers in Pharmacology*. 8:942. https://doi.org/10.3389/fphar.2017.00942

Brincat, A., Stewart, D., Vella Bonanno, P., Weidmann, A. 2018. Patients' lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours: a systematic review. 2018, Available from: http://www.crd.york.ac.uk/PROSPERO/export_record_pdf.php [Accessed 21st August 2018]

Brincat, A., Stewart, D., Vella Bonanno, P., Weidmann. A.E. 2018. Patients' lived experiences with antineoplastic medicines prescribed for the management of malignant solid tumours: a systematic review. ESCP International Workshop Expanding roles and opportunities for the pharmacist in optimizing use of oral cancer drugs. 19–20 February 2018, Reykjavik, Iceland [Oral presentation] Abstract published in Int J Clin Pharm. 2018, 40:730–736.
https://link.springer.com/article/10.1007/s11096-018-0637-5
https://doi.org/10.1007/s11096-018-0637-5

Brincat, A., Stewart, D., Vella Bonanno, P., Weidmann, A.E. 2018. Systematic review contributing to an understanding of the patients' lived experience with medicines with reference to antineoplastic medicines. International Social Pharmacy Workshop – The changing landscape of social pharmacy: balancing safety, technology, efficiency and outcomes. 23-26 July 2018, Leuven, Belgium [Oral presentation]
Abstract published in Research in Social and Administrative Pharmacy. 2018, 14:e623-e56
https://www.sciencedirect.com/science/article/abs/pii/S1551741118304601
https://doi.org/10.1016/j.sapharm.2018.05.023

Godman B., Bucsics A., Vella Bonanno P., Oortwijn W., Rothe CC, Ferrario A., Bosselli S., Hill A., Martin AP., Simoens S., Kurdi A., Gad M., Gulbinovič J., Timoney A., Bochenek T., Salem A., Hoxha I., Sauermann R., Massele A., Guerra AA., Petrova G., Mitkova Z., Achniotou G., Laius O., Sermet C., Selke G., Kourafalos V., Yfantopoulos J., Magnusson E., Joppi R., Oluka M., Kwon HY., Jakupi A., Kalemeera F., Fadare JO., Melien O., Pomorski M., Wladysiuk M., Marković-Peković V., Mardare I., Meshkov D., Novakovic T., Fürst J., Tomek D., Zara C., Diogene E., Meyer JC., Malmström R., Wettermark B., Matsebula Z., Campbell S., Haycox A. 2018. Barriers for Access to New Medicines: Searching for the balance between rising costs and limited budgets. *Frontiers in Public Health*. 6:328. doi: 10.3389/fpubh.2018.00328
https://www.frontiersin.org/article/10.3389/fpubh.2018.00328
https://www.ncbi.nlm.nih.gov/pubmed/30568938

Vella Bonanno P., Bucsics A., Simoens S., Martin AP., Oortwijn W., Gulbinovič J., Rothe C., Timoney A., Ferrario A., Gad M., Salem A., Hoxha I., Sauermann R., Kamusheva M., Dimitrova M., Laius O., Selke G., Kourafalos V., Yfantopoulos J., Magnusson E., Joppi R., Jakupi A., Bochenek T., Wladysiuk M., Furtado C., Marković-Peković V., Mardare I., Meshkov D., Fürst J., Tomek D., Cortadellas MO., Zara C., Haycox A., Campbell S., Gadman B. 2019. Proposal for a Regulation on Health Technology Assessment in Europe – opinions of policy makers, payers and academics from the field of HTA. *Expert Review of Pharmacoeconomics & Outcomes Research*. https://doi.org/10.1080/14737167.2019.1575730

Godman B., Hill A., Simoens S., Kurdi A., Gulbinovič J., Martin AP., Timoney A., Gotham D., Wale J., Bochenek T., Rothe C., Hoxha I., Malaj A., Hierländer C., Sauermann R., Hamelinck W., Mitkova Z., Petrova G., Laius O., Sermet C., Langer I., Selke G., Yfantopoulos J., Joppi R., Jakupi A., Poplavska E., Greiciute-Kuprijanov L., Vella Bonanno P., Piepenbrink JF., de Valk V., Hagen C., Ringerud AM., Plisko R., Wladysiuk M., Marković-Peković V., Grubiša N, Ponorac T., Mardare I., Novakovic T., Parker M., Fürst J., Tomek D., Cortadellas M., Zara C., Juhasz-Haverinen M., Skiold P., McTaggart S., Haycox A . 2019. Pricing of oral generic cancer medicines in 25 European countries; findings and implications. *GABI Journal*, vol. 8, issue 2, pp. 1-22.

Brincat, A., Vella Bonanno, P., Stewart, D., Weidmann, A. 2019. Patients' lived experiences with antineoplastic medicines for the management of malignant solid tumours: A systematic review. *Research in Social and Administrative Pharmacy,* https://doi.org/10.1016/j.sapharm.2019.06.020.

Pontes C., Zara C., Torrent-Farnell J., Obach M., Nadal C., Vella-Bonanno P., Ermisch M., Simoens S., Hauegen RC., Gulbinovic J., Timoney A., Martin AP., Mueller T., Nachtnebel A., Campbell S., Selke G., Bochenek T., Rothe CC., Mardare I., Bennie M., Furst J., Malmstrom RE., Godman B. 2019. Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case of Olaratumab. *Applied Health Economics and Health Policy,* Nov 7 https://www.ncbi.nlm.nih.gov/pubmed/31696433

Vella Bonanno P. 2019. Attitudes, perceived impacts and motivational factors for European Member State Collaboration for pricing and reimbursement of medicines: a review of the evidence. Dissertation submitted in partial fulfilment of the requirements of the Degree of MA in Management at the University of Malta.

Vella Bonanno P., Morton A. and Godman B. 2020, "Structured Expert Judgement for decisions on medicines policy and management" in Bedford T., French S., Hanea A.M., Nanr G.F. (eds.) *Expert judgement in risk and decision analysis*, International Series in Operations Research and Management Science, Springer Nature Switzerland AG. (in publication).